Evidence map›Paper›PMID 40458727›Full record

ReviewFrontiers in oncology2025

Novel insights into the N 6-methyladenosine modification on circRNA in cancer.

Qingling Xu, Yi Jia, Ying Liu, Bing Wu, Jianxun Wang, Xiang Ao, Wei Ding

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qingling Xu *Department of Comprehensive Internal Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Yi Jia *Department of Comprehensive Internal Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Ying LiuInstitute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao Medical College, Qingdao University, Qingdao, Shandong, China.
Bing WuInstitute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao Medical College, Qingdao University, Qingdao, Shandong, China.
Jianxun WangSchool of Basic Medicine, Qingdao University, Qingdao, Shandong, China.
Xiang AoDepartment of Comprehensive Internal Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Wei DingDepartment of Comprehensive Internal Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circular RNAs (circRNAs) are a class of non-coding RNAs (ncRNAs) generated through the reverse splicing of mRNA precursors (pre-mRNAs). They possess a unique loop structure and exhibit remarkable stability. CircRNAs have emerged as promising biomarkers for cancer, with specific circRNAs playing crucial roles in cancer drug discovery, treatment, and resistance mechanisms. N6 methyl adenosine (m6A) represents the most prevalent RNA modification in eukaryotes. In 2017, researchers identified that m6A modifications also occur in circRNAs, displaying unique characteristics. m6A-modified circRNAs undergo reversible regulation mediated by enzymes involved in m6A modification pathways. These modified circRNAs interact with m6A-binding proteins, thereby influencing processes such as alternative splicing, translation and degradation. Some circRNAs enhance their metabolism or facilitate nuclear export to the cytoplasm by interacting with enzymes involved in m6A regulation. The study of m6A-modified circRNAs has gained great attention in circRNA research due to their association with various diseases. This review summarizes the functional mechanisms of circRNAs regulated by m6A modifications and their implications in cancer occurrence and therapy, with a primary focus on the genesis, regulatory mechanisms, and functional roles of m6A-modified circRNAs in the biology of diverse types of cancers. Additionally, we explore the potential application of m6A-modified circRNAs in clinical cancer treatment.

Indexed as

cancercircRNAdrug resistancem6A modificationN6-methyladenosine

Identifiers

PMID40458727
PMCPMC12127328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.